Resmed Inc
SWB:RME
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
R
|
Resmed Inc
SWB:RME
|
US |
|
S
|
Sumitomo Mitsui Financial Group Inc
DUS:XMF
|
JP |
|
Albertsons Companies Inc
F:27S
|
US |
|
Dian Swastatika Sentosa Tbk PT
IDX:DSSA
|
ID |
|
N
|
Nike Inc
DUS:NKE
|
US |
|
U
|
United States Steel Corp
XETRA:USX1
|
US |
|
T
|
TFS Financial Corp
XBER:PWT
|
US |
|
N
|
Neogenomics Inc
F:NG9
|
US |
|
D
|
Darling Ingredients Inc
XBER:43D
|
US |
|
B
|
Brightview Holdings Inc
F:7BV
|
US |
Wall St Price Targets
RME Price Targets Summary
Resmed Inc
According to Wall Street analysts, the average 1-year price target for RME is 235.07 EUR with a low forecast of 154.82 EUR and a high forecast of 304.03 EUR.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is RME's stock price target?
Price Target
235.07
EUR
According to Wall Street analysts, the average 1-year price target for RME is 235.07 EUR with a low forecast of 154.82 EUR and a high forecast of 304.03 EUR.
What is the Revenue forecast for Resmed Inc?
Projected CAGR
7%
Over the last 13 years, the compound annual growth rate for Revenue has been 11%. The projected CAGR for the next 6 years is 7%.
What is the Operating Income forecast for Resmed Inc?
Projected CAGR
11%
Over the last 13 years, the compound annual growth rate for Operating Income has been 14%. The projected CAGR for the next 5 years is 11%.
What is the Net Income forecast for Resmed Inc?
Projected CAGR
12%
Over the last 13 years, the compound annual growth rate for Net Income has been 14%. The projected CAGR for the next 6 years is 12%.
